Market Overview

Horizon to Acquire US Rights for VIMOVO from Pozen

Related POZN
Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Q4 Profit Drops
POZEN And Tribute Announce Plan To Proceed With Merger To Form Aralez Pharmaceuticals, $350 Million Capital Commitment from Deerfield-Led Syndicate

announced that AstraZeneca AB (NYSE: AZN) and Horizon Pharma USA, Inc. (NASDAQ: HZNP) have entered into an agreement for Horizon to acquire the U.S.
rights for VIMOVO® (naproxen / esomeprazole magnesium)
delayed release tablets. Under the terms of the agreement, POZEN will
continue to receive a 10% royalty on Net Sales of products sold in the
United States, with guaranteed annual minimum royalty payments of $5
million in 2014, and $7.5 million each year thereafter, provided that
the patents owned by POZEN which cover VIMOVO® are in effect
and no generic forms of VIMOVO® are on the market. Also under
the agreement, Horizon has assumed AstraZeneca's right to lead the

See full press release

Posted-In: News Guidance Contracts Management M&A Global


Related Articles (AZN + HZNP)

View Comments and Join the Discussion!

Partner Center